AstraZeneca’s chief executive, Sir Pascal Soriot, tops the list with £16.85m, High Pay Centre research reveals.

Big pharma chair Michel Demaré points to proxy advisors as cause of block on higher pay while more FTSE 100 companies plan boost to packages.

Almost 40% of AstraZeneca shareholders deliver a blow to the pharmaceuticals company, by voting against its annual remuneration report.